Multidisciplinary Research Center for Malignant Hemopathies

In the last decades we have experienced an increase in hematological malignancies, due to this, the hematological area of research has gained more and more attention. Although newer classifications of hematologic diseases include a variety of genetic abnormalities,  Flow cytometric immunophenotyping is still an indispensable tool for diagnosis, classification, staging, and monitoring of hematologic neoplasms.

Phenotypically abnormal populations have been documented in many hematologic neoplasms, including lymphoma, chronic lymphoid leukemias, plasma cell neoplasms, acute leukemia, paroxysmal nocturnal hemoglobinuria, mast cell disease, myelodysplastic syndromes, and myeloproliferative disorders. In addition, flow cytometry is a useful tool for staging a previously diagnosed hematolymphoid neoplasm, monitoring response to treatment including detection of minimal residual disease (MRD), documenting relapse or progression, and diagnosing an intercurrent hematologic malignancy.  Moreover, the provision of immunophenotypic information may have additional value, including the identification of targets for a potential targeted therapy.

Nowadays, hematology endorses a multiparametric approach to diagnosis and outlines the morphologic, immunophenotypic, and genotypic features characteristic of each disease entity. With this in mind, our center plans to corroborate preclinical and clinical investigations and gain more knowledge of the phenotypes of diverse normal cell populations and recognize deviations from the normal to be able to discuss the potential clinical significance of the flow cytometric findings.

We are open to collaboration in the fields of genetics, molecular biology, anatomopathology, immunology, pharmacology, cardiotoxicity.